SG11202103849TA - Anti-periostin antibodies and uses thereof - Google Patents

Anti-periostin antibodies and uses thereof

Info

Publication number
SG11202103849TA
SG11202103849TA SG11202103849TA SG11202103849TA SG11202103849TA SG 11202103849T A SG11202103849T A SG 11202103849TA SG 11202103849T A SG11202103849T A SG 11202103849TA SG 11202103849T A SG11202103849T A SG 11202103849TA SG 11202103849T A SG11202103849T A SG 11202103849TA
Authority
SG
Singapore
Prior art keywords
periostin antibodies
periostin
antibodies
Prior art date
Application number
SG11202103849TA
Other languages
English (en)
Inventor
Arif Jetha
Johan Fransson
Aj Mcgray
Joanne Hulme
Original Assignee
Boehringer Ingelheim Io Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Io Canada Inc filed Critical Boehringer Ingelheim Io Canada Inc
Publication of SG11202103849TA publication Critical patent/SG11202103849TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202103849TA 2018-12-14 2019-12-13 Anti-periostin antibodies and uses thereof SG11202103849TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779996P 2018-12-14 2018-12-14
US201962899075P 2019-09-11 2019-09-11
PCT/IB2019/001307 WO2020121059A1 (en) 2018-12-14 2019-12-13 Anti-periostin antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11202103849TA true SG11202103849TA (en) 2021-05-28

Family

ID=71075443

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103849TA SG11202103849TA (en) 2018-12-14 2019-12-13 Anti-periostin antibodies and uses thereof

Country Status (21)

Country Link
US (1) US20220010003A1 (zh)
EP (1) EP3894439A4 (zh)
JP (2) JP2022513228A (zh)
KR (1) KR20210108972A (zh)
CN (1) CN113631571A (zh)
AU (1) AU2019395887A1 (zh)
BR (1) BR112021010634A2 (zh)
CA (1) CA3120059A1 (zh)
CL (1) CL2021001297A1 (zh)
CO (1) CO2021007444A2 (zh)
CR (1) CR20210310A (zh)
DO (1) DOP2021000113A (zh)
EC (1) ECSP21043288A (zh)
IL (1) IL283890A (zh)
JO (1) JOP20210144A1 (zh)
MA (1) MA54472A (zh)
MX (1) MX2021007043A (zh)
PE (1) PE20211962A1 (zh)
SA (1) SA521422250B1 (zh)
SG (1) SG11202103849TA (zh)
WO (1) WO2020121059A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114364400A (zh) * 2019-09-11 2022-04-15 勃林格殷格翰国际加拿大公司 使用pd-1轴抑制剂及抗骨膜蛋白抗体治疗癌症的方法
KR20240038198A (ko) 2022-09-15 2024-03-25 한남대학교 산학협력단 인슐린 분비 베타세포 분화 유도 항체 및 이를 유효성분으로 포함하는 대사성 질환 예방 또는 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP2366713A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EA200801865A1 (ru) * 2006-02-22 2009-02-27 Филоджен Спа Опухолевые маркеры сосудов
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
EA201490576A1 (ru) * 2011-09-15 2014-09-30 Нэшенел Юнивёрсити Корпорейшен Нагоя Юнивёрсити Молекулярный маркер для ранней диагностики мезотелиомы плевры у пациентов и способы для анализа его экспрессии
ES2811060T3 (es) * 2013-03-08 2021-03-10 Univ Osaka Anticuerpo contra péptido codificado por exón-21 de periostina y composición farmacéutica para prevenir o tratar enfermedades asociadas a inflamación que contienen el mismo
GB201419084D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
EP3349787A4 (en) * 2015-09-18 2019-03-27 Arch Oncology, Inc. THERAPEUTIC CD47 ANTIBODIES

Also Published As

Publication number Publication date
WO2020121059A1 (en) 2020-06-18
CA3120059A1 (en) 2020-06-18
KR20210108972A (ko) 2021-09-03
AU2019395887A1 (en) 2021-05-20
CL2021001297A1 (es) 2022-01-07
JOP20210144A1 (ar) 2023-01-30
BR112021010634A2 (pt) 2021-11-16
DOP2021000113A (es) 2021-09-30
MX2021007043A (es) 2021-08-11
US20220010003A1 (en) 2022-01-13
PE20211962A1 (es) 2021-10-04
EP3894439A1 (en) 2021-10-20
CN113631571A (zh) 2021-11-09
CO2021007444A2 (es) 2021-09-30
JP2022513228A (ja) 2022-02-07
CR20210310A (es) 2021-11-24
JP2023139243A (ja) 2023-10-03
EP3894439A4 (en) 2022-11-30
IL283890A (en) 2021-07-29
MA54472A (fr) 2022-03-23
SA521422250B1 (ar) 2023-12-21
ECSP21043288A (es) 2021-09-30

Similar Documents

Publication Publication Date Title
IL276950A (en) Anti-CD73 antibodies and uses thereof
IL282968A (en) Anti-NKG2A antibodies and their use
IL267942B (en) Anti-cd73 antibodies and uses thereof
IL271477A (en) Anti-cd166 antibodies and their uses
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
IL268700A (en) Anti-PHF-tau antibodies and uses thereof
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL269134A (en) Antibodies against PAR2 and their use
IL275826A (en) Anti-mct1 antibodies and their uses
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
IL289585A (en) DLL3-targeted antibodies and uses thereof
IL281297A (en) Anti-NPR1 antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL277330A (en) Anti-IL-27 antibodies and uses thereof
IL271398A (en) Anti-l1-cam antibodies and uses thereof
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
SG11202112112UA (en) Anti-galectin-9 antibodies and uses thereof
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
IL276548A (en) Binding antibodies - BCMA and their uses
IL291546A (en) Antibodies against kir3dl3 and their uses